Structured lifestyle program and PhenoAge in Arab adults with prediabetes
In this 6-month randomized trial in Arab adults with prediabetes, a structured lifestyle program reduced PhenoAge by 4.9 years on average, while the control group rose by 1.3 years; GDF-15 and sclerostin changes appeared time-dependent rather than program-specific. [1]
Automatic summary · not editorially reviewed
The key findings
The trial enrolled 181 Arab adults with prediabetes and followed them for 6 months, comparing a structured lifestyle program with a control group that received a brochure. [1]
PhenoAge fell by 4.9 years in the lifestyle program versus a 1.3-year rise in the control group, with a reported between-group p value. [1]
Changes in GDF-15 and sclerostin appeared time-dependent rather than specific to the intervention. [1]
The source at a glance
- Study type / format
- Randomized clinical trial (abstract)
- Population / context
- Arab adults with prediabetes (181 participants; 130 males, 51 females; mean age 50.8 years; mean BMI 30.0).
- Summary based on
- Study abstract
- Original publication
- September 10, 2026
PhenoAge as primary endpoint in prediabetes trial
The abstract describes a randomized clinical trial with 181 Arab adults with prediabetes (130 males, 51 females; mean age 50.8 years; mean BMI 30.0). Participants were assigned to a structured lifestyle modification program or a control group and followed for 6 months. The program asked for a 5% weight reduction, moderate exercise of 150 minutes per week, fat intake reduced to 30% and fiber intake increased by 15 g per 1 kcal; the control group received a brochure. PhenoAge was the primary endpoint, with sclerostin and GDF-15 as secondary endpoints.
Supporting source [1]
PhenoAge fell 4.9 years versus 1.3-year rise
Compared with the control group, participants in the lifestyle program showed a significant reduction in PhenoAge: -4.9 versus +1.3 years, with a between-group p value reported in the abstract. The conclusion states that the intervention significantly improved PhenoAge, accompanied by improvements in metabolic parameters. Changes in GDF-15 and sclerostin appeared time-dependent rather than specific to the intervention. The authors describe these findings as supporting lifestyle modification as a potential strategy to slow a composite clinical measure of biological aging.
Supporting source [1]
Abstract-only scope of the 6-month trial
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports a 6-month follow-up and a randomized design but does not give the full statistical details, adverse events or long-term outcomes. PhenoAge is described as a composite clinical measure of biological aging, not as a direct measure of lifespan. The reported associations come from a single trial in Arab adults with prediabetes and should not be read as proof that the program extends life or as personal advice.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report full statistical details, adverse events or long-term outcomes, and the 6-month trial covers Arab adults with prediabetes only. PhenoAge is a composite clinical measure, not a direct lifespan measure.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Alenezi A, Sabico S, Alnaami AM, Hussain SD, Elrobh MS, Al-Daghri NM. · europepmc.org · September 10, 2026